Prevalence of psoriasis in China: A population-based study in six cities

Ding, Xifeng; TingLin, Wang; Shen, Yiwei; Wang, Xiaoyan; Zhou, Cheng; Tian, Sugui; Liu, Ying; Guang-hui, Peng; JunE, Zhou; Xue, Shimin; Ren-li, Wang; Tang, Ying; Meng, Xiangyi; GuangDe, Pei; Bai, Yunhua; Liu, Qing; Li, Hang; Zhang, Jianzhong

doi:10.1684/ejd.2012.1802

Cited by 185 publications

(155 citation statements)

References 15 publications

(21 reference statements)

Supporting

Mentioning

135

Contrasting

Order By: Relevance

“…Unlike classical bimodal peaks in distribution patterns of age at diagnosis in western studies, which showed peaks located in the late teens and late 50s, Asian studies46, including ours, showed dual peaks located in the 20s and 40s. Additionally, early-onset (type 1, <40 years) psoriasis accounted for more than 75% of patients in western studies8 and 67.6% of patients in the Chinese study6, but only 53.9% in our study.…”

Section: Discussioncontrasting

confidence: 92%

“…The mean age of patients in our study (47.0 years) was higher than that observed in hospital based Japanese studies (45.5 years4 and 44.7 years5) as well as a Chinese population-based study (41.8 years6), but was similar to a Taiwanese cohort study (46.4 years7). Unlike classical bimodal peaks in distribution patterns of age at diagnosis in western studies, which showed peaks located in the late teens and late 50s, Asian studies46, including ours, showed dual peaks located in the 20s and 40s.…”

Section: Discussionsupporting

confidence: 48%

See 1 more Smart Citation

The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)

et al. 2017

View full text Add to dashboard Cite

BackgroundPsoriasis is an immune-mediated, chronic inflammatory disease affecting multiple aspects of patients' lives. Its epidemiology varies regionally; however, nationwide epidemiologic data on psoriasis depicting profile of Korean patients has not been available to date.ObjectiveTo understand nationwide epidemiologic characteristics and clinical features of adult patients with psoriasis visited university hospitals in Korea.MethodsThis multicenter, non-interventional, cross-sectional study recruited 1,278 adult patients with psoriasis across 25 centers in Korea in 2013. Various clinical data including PASI, BSA, DLQI, SF-36 and PASE were collected.ResultsA total of 1,260 patients completed the study (male:female=1.47:1). The mean age was 47.0 years with a distribution mostly in the 50s (24.9%). Early onset (<40 years) of psoriasis accounted for 53.9% of patients. The mean disease duration was 109.2 months; mean body mass index was 23.9 kg/m2; and 12.7% of patients had a family history of psoriasis. Plaque and guttate types of psoriasis accounted for 85.8% and 8.4%, respectively. Patients with PASI ≥10 accounted for 24.9%; patients with body surface area ≥10 were 45.9%. Patients with DLQI ≥6 accounted for 78.8%. Between PASI <10 and PASI ≥10 groups, significant difference was noted in age at diagnosis, disease duration, blood pressure, waist circumference of female, and treatment experiences with phototherapy, systemic agents, and biologics.ConclusionThis was the first nationwide epidemiologic study of patients with psoriasis in Korea and provides an overview of the epidemiologic characteristics and clinical profiles of this patient population.

show abstract

Section: Discussioncontrasting

confidence: 92%

Section: Discussionsupporting

confidence: 48%

The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The prevalence rates of psoriasis in Europe vary between 0.73% (in Scotland) and 2.9% (in Italy), and rates reported in United States vary between 0.7% and 2.6%, which shows a worldwide geographic variation [1]. In China, the incidence of psoriasis has increased to 0.47% [2], showing an upward trend of 0.12% compared to 1984 [3]. Psoriasis is characterized by scaly, erythematous patches, papules, and plaques that are often severely pruritic.…”

Section: Introductionmentioning

confidence: 99%

“…Symptoms such as poor esteem, sexual dysfunction, anxiety, depression, and suicidal ideation due to the appearance of skin, can significantly reduce the patients’ health-related quality of life. For instance, in China, 59.8% of psoriatic people experience negative influences on quality of life [2]. It has been a cause of increasing concern worldwide due to its high-prevalence and its harmful and incurable characteristics.…”

Section: Introductionmentioning

confidence: 99%

Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial

Wen

Xuan²,

Yan³

et al. 2014

Trials

View full text Add to dashboard Cite

BackgroundPsoriasis causes worldwide concern because of its high-prevalence, as well as its harmful, and incurable characteristics. Topical therapy is a conventional treatment for psoriasis vulgaris. Chinese medicine (CM) has been commonly used in an integrative way for psoriasis patients for many years. Some CM therapies have shown therapeutic effects for psoriasis vulgaris (PV), including relieving symptoms and improving quality of life, and may reduce the relapse rate. However, explicit evidence has not yet been obtained. The purpose of the present trial is to examine the efficacy and safety of the YXBCM01 granule, a compound Chinese herbal medicine, with a combination of topical therapy for PV patients.Methods/DesignUsing an add-on design, the trial is to evaluate whether the YXBCM01 granule combined topical therapy is more effective than topical therapy alone for the treatment of PV. The study design is a double-blind, parallel, randomized controlled trial comparing the YXBCM01 granule (5.5 g twice daily) to a placebo. The duration of treatment is 12 weeks. A total of 600 participants will be randomly allocated into two groups, YXBCM01 granule group and placebo group, from 11 general or dermatological hospitals in China. Topical use of calcipotriol betamethasone for the first 4 weeks and calcipotriol ointment for the remaining 8 weeks will be the same standard therapy for the two groups. Patients will be enrolled if they have a clinical diagnosis of PV, a psoriasis area severe index (PASI) of more than 10 or body surface area (BSA) of more than 10%, but PASI of less than 30 and BSA of less than 30%, are aged between 18 and 65-years-old, and provide signed informed consent. The primary outcome, relapse rate, is based on PASI assessed blindly during the treatment. Secondary outcomes include: (i) relapse time interval, (ii) time to onset, (iii) rebound rate, (iv) PASI score, (v) cumulative consumption of medicine, (vi) the dermatology quality life index (DLQI), and (vii) the medical outcomes study (MOS) item short form health survey (SF-36). Analysis will be on intention-to-treat and per-protocol subject analysis principles.DiscussionTo address the effectual remission of the YXBCM01 granule for PV, this trial may provide a novel regimen for PV patients if the granule can decrease relapse rate without more adverse effects.Trial registrationChinese Clinical Trial Registry (http://cwww.chictr.org): ChiCTR-TRC-13003233, registered 26 May 2013.

show abstract

“…Psoriasis vulgaris was observed in all the 24 patients,which is the most common psoriasis type in China [5]. Increasing evidence suggests that psoriasis is associated with diabetes, metabolic syndrome, and cardiovascular disease, independent of traditional risk factors [39–41].…”

Section: Discussionmentioning

confidence: 99%

PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy

Jin

Zeng

et al. 2016

BMC Nephrol

View full text Add to dashboard Cite

BackgroundThe association between psoriasis and membranous nephropathy (MN) remains largely unclear. We examined the prevalence of serum PLA2R antibody and characterized the expression of PLA2R and THSD7A in glomeruli in patients with MN and psoriasis.MethodsA total of 24 patients with MN without evidence of a secondary cause except psoriasis were enrolled. The clinical and pathological features were retrospectively analyzed. Serum anti-PLA2R antibody was measured using IFA Mosaic. Renal tissue samples stored in the laboratory bio-bank were used for PLA2R staining under immunofluorescence microscopy and THSD7A immunohistochemical analysis.ResultsTwenty-four patients (21 male and 3 female) with a mean age of 43.6 ± 15.7 years old were enrolled. Serum anti-PLA2R antibody was positive in 7 patients, which was significantly lower than the positivity observed in idiopathic MN (29.2% vs. 81.7%, P < 0.001). Glomerular PLA2R staining was positive in 7 patients with positive serum anti-PLA2R antibody. THSD7A staining was negative in all 24 patients. During the follow-up visits, 13 patients with negative serum PLA2R antibody achieved CR. In contrast, CR was only achieved in 1 patient with positive serum PLA2R antibody, PR was achieved in 2 patients.ConclusionsThe prevalence of serum anti-PLA2R antibody and glomerular expression of PLA2R was significantly lower in patients with psoriasis and MN than in those with idiopathic MN, and THSD7A staining was negative, suggesting that MN is associated with psoriasis in the majority of patients. However, idiopathic MN might also accompany psoriasis in a minority of psoriatic patients with positive serum anti-PLA2R antibody.

show abstract

Prevalence of psoriasis in China: A population-based study in six cities

Cited by 185 publications

References 15 publications

The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)

The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)

Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial

PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy

Contact Info

Product

Resources

About